Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Huazhong University of Science and Technology

Status and phase: Unknown; Phase 4

Conditions: Hypertension

Treatments: Drug: candesartan cilexetil

Study type: Interventional

Funder types: Other

Identifiers

NCT00360763

UH-01

Details and patient eligibility

About

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertension (2 grade)

Exclusion criteria

• Secondary hypertension
• Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)